Medicines labeled for the same conditions
Alternatives to rucaparib camsylate
8 other medicines are given the same way (oral) and in the same FDA class as rucaparib camsylate or labeled mainly for the same use (prostate cancer); 3 are in its class, poly(adp-ribose) polymerase inhibitors: talazoparib, olaparib and abiraterone and niraparib; the others include 2 androgen receptor inhibitors, 1 cytochrome p450 17a1 inhibitor and 1 gonadotropin releasing hormone receptor antagonist (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as rucaparib camsylate?
Prostate cancer lists all 17 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Rucaparib camsylatepoly(adp-ribose) polymerase inhibitor | this medicine | none listed | n/a | No | No current entry |
| Talazoparibpoly(adp-ribose) polymerase inhibitor · same class | Prostate cancer | none listed | n/a | No | No current entry |
| Olaparibpoly(adp-ribose) polymerase inhibitor · same class | Prostate cancer | none listed | n/a | No | No current entry |
| Abiraterone and niraparibcytochrome p450 17a1 inhibitor · same class | Prostate cancer | none listed | n/a | No | No current entry |
| Abirateronecytochrome p450 17a1 inhibitor | Prostate cancer | 24 labelers | $0.774 per tablet 250 mg tablet | No | No current entry |
| Enzalutamideandrogen receptor inhibitor | Prostate cancer | none listed | n/a | No | No current entry |
| Apalutamide | Prostate cancer | none listed | n/a | No | No current entry |
| Nilutamideandrogen receptor inhibitor | Prostate cancer | 1 labeler | n/a | Yes | A presentation being discontinued |
| Relugolixgonadotropin releasing hormone receptor antagonist | Prostate cancer | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Rucaparib camsylate: the full record
- label, generics, price, shortages, recalls